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Abstract
Background: Gestational diabetes mellitus (GDM), a hyperglycemic state detected during pregnancy, is an
established risk factor for diabetes. However, treatment during pregnancy in and of itself is not able to eliminate
this risk, and a considerable fraction of women with GDM will develop frank diabetes in the decade following
pregnancy. Our aim is to conduct a multicenter randomized controlled trial to investigate the effectiveness of a
lifestyle intervention program implemented after a pregnancy complicated by GDM in delaying or preventing the
development of type 2 diabetes.
Methods: Women aged 18 or older identified as having recent GDM are recruited and followed by telephone to
assess eligibility for the trial. To be eligible, women must have used insulin during pregnancy or present intermediate
hyperglycemia postpartum. Women are encouraged to enter the trial as early as 10 weeks, and are permitted to do so
up to 2 years after a pregnancy with GDM. An estimated 740 women will be randomized to either conventional care
or to coach-based interventions focused on breastfeeding, weight loss, healthy eating, and increased physical activity,
and predominantly delivered by telephone. Women are followed annually to detect new onset diabetes, the primary
outcome, and additional secondary outcomes which include reversion to normoglycemia, weight loss, physical activity
and fitness, and insulin resistance.
Discussion: Though previous studies have demonstrated that type 2 diabetes can be delayed or prevented, no study
has yet demonstrated the feasibility and effectiveness of similar interventions implemented in the postpartum period
for women with recent GDM. If shown to be successful, this approach could become an important means of
preventing diabetes in primary care settings.
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Background
Diabetes is a major cause of morbidity and mortality and
is one of the four main chronic diseases identified by the
World Health Organization as the focus for prevention
and control [1]. Diabetes can be prevented, as shown by
two landmark clinical trials, the Diabetes Prevention
Program (DPP) and the Diabetes Prevention Study
(DPS): an average of three years of lifestyle interventions
can reduce by 58 % the incidence of type 2 diabetes in
individuals presenting impaired glucose tolerance [2, 3].
Subgroup analyses of one of these trials, focusing on
women with previous gestational diabetes mellitus
(GDM), found a 53 % reduction at the end of the trial
[4] and a 35 % reduction 10 years later [5].
GDM, a hyperglycemic state detected during preg-
nancy, is an established risk factor for diabetes [6] but
treatment during pregnancy in and of itself is not able to
eliminate its risk [7]. Although a clinical trial showed
that troglitazone could reduce diabetes incidence by
55 % when applied to very high risk women with GDM,
the drug was subsequently withdrawn from the market
due to serious adverse effects [8].
More recent randomized trials are testing the effect of
lifestyle interventions after pregnancy among women
with GDM with the aim of preventing diabetes. One
such trial randomized 450 women with GDM and im-
paired glucose tolerance postpartum in China and found
that the incidence of diabetes did not differ between the
intervention (15 %) and the control group (19 %), after
36 months of follow up [9]. Four other trials are on-
going. One, in China, is randomizing 1180 women with
GDM diagnosed over a prior 5-year period [10]. An-
other, in Australia, is randomizing women at postpartum
with the aim of reducing diabetes risk at 12 months
postpartum [11]. A third is a pragmatic cluster random-
ized clinical trial of 44 medical facilities at Kaiser Perma-
nente Northern California including 2320 women with
GDM, having as primary outcomes postpartum weight
goals at 6 and 12 months [12]. Finally, an additional ran-
domized trial is testing the efficacy of an individually-
tailored lifestyle intervention to reduce risk factors for
type 2 diabetes and cardiovascular disease among post-
partum Hispanic women with a history of abnormal glu-
cose tolerance during pregnancy [13].
Rationale for the trial and for the choice of the
interventions
Given the increased burden of diabetes worldwide, pre-
ventive actions are urgently needed. Lifestyle modifica-
tions have been shown to be effective in the prevention
of diabetes when offered to high risk middle-age individ-
uals, but identification of those at risk is challenging.
Pregnancy is a good opportunity to identify women at
risk since glucose testing is routinely done for the
detection of gestational diabetes. Since retesting at post-
partum is also routinely recommended for these women,
those found to be at higher risk can be targeted for early
diabetes prevention. Moreover, lifestyle interventions are
usually implemented during pregnancy for the treatment
of gestational diabetes. Since women frequently abandon
these lifestyle changes after pregnancy, interventions to
encourage a healthy lifestyle are needed and must be tai-
lored to the postpartum period so as to take into ac-
count the difficulties involved in this setting of adapting
to the needs of the new baby.
Motivational interviewing [14] and other communica-
tion strategies [15, 16] may help tailor the intervention
to women’s health needs and stimulate behavioral
change in the context of coping with the demands of
motherhood. The choice of the interventions must be
focused on the potential benefits for these women at this
particular phase of their lives. In this regard, a few inter-
ventions are especially suitable, as discussed below.
Breastfeeding, a healthy behavior in and of itself, has
been associated with improved maternal metabolic pro-
files when assessed by observational studies [17]. Breast-
feeding was associated with lower blood glucose levels
6–12 weeks postpartum in women with GDM [18],
greater postpartum weight loss [19], lower risk of obesity
in the long run, as well as lower risk for the metabolic
syndrome [20, 21]. Breastfeeding exclusively for
6 months, and to any extent for 12 months, reduced
weight retention at 6 months postpartum, irrespective of
pre-pregnancy body mass index (BMI); and at 18 months
postpartum in women with BMI < 35 kg/m2 [22, 23].
Moreover, a decreased risk of diabetes has been found
for breastfeeding women with and without GDM, al-
though not in all studies [22, 24–27]. Despite these po-
tential benefits, obese women have shorter lengths of
exclusive and overall breastfeeding [28, 29], and those
obese and also with diabetes or GDM, lower rates of
intending and initiating breastfeeding [30].
Weight control interventions to facilitate achieving pre-
pregnancy weight and further weight loss at postpartum
are fundamental for the prevention of diabetes, as major
diabetes prevention trials have shown that a loss of about
5 % of body weight is associated with a decreased incidence
of diabetes [2, 3]. Pre-pregnancy weight [31], pregnancy
weight gain and retention of weight at postpartum [7] are
common and important risk factors for type 2 diabetes in
GDM women. A recent Brazilian pregnancy cohort re-
ported excessive weight gain in 44.8 % of women, being
more frequent among those who were overweight prior to
pregnancy [32]. The same study found median weight re-
tention at 4–6 months postpartum of 4.4 kg, with 33 % of
women moving to a higher BMI category and an additional
15 % of women who were already overweight gaining add-
itional weight without a change of BMI category.
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Evidence summarized by a Subcommittee on Nutrition
During Lactation (Institute of Medicine) shows that lac-
tating women typically lose weight at the rate of 0.5 to
1.0 kg per month in the first 4 to 6 months of lactation,
probably related to physiologic changes during this
period. The Committee also noted that some women
lose as much as 2 kg per month and successfully main-
tain milk volume. The Subcommittee recommended that
during lactation daily energy intake should not be re-
stricted to less than 1800 kcal and especially not to less
than 1500 kcal [28].
Further studies have demonstrated that to promote a
weight loss of 2 kg/month (0.5 kg/week), overweight lac-
tating women may restrict their usual energy intake by
500 kcal/day and exercise aerobically 4 days/week [33].
A Cochrane systematic review supports the feasibility
and safety of moderate dietary restrictions (alone or in
combination with exercise) for postpartum weight loss
[34]. A further systematic review demonstrated that ex-
ercise strategies in postpartum women, with or without
dietary intervention, improve weight loss compared with
usual care [35]. A recent trial based on 2.5 h of individ-
ual sessions and biweekly phone interaction to stimulate
weight loss through healthy diet and physical activity
found that a 12-weeks intervention in lactating women
(overweight or obese before pregnancy) produced an
average weight loss of 8.3 kg shortly after the interven-
tion and of 10.2 kg at 1-y follow-up [36], with improve-
ment of cardiovascular risk factors [37]. However, given
the high level of education of these women, it is import-
ant to consider also the more modest effects observed in
a pilot study of lifestyle interventions for women with
GDM during pregnancy and the postpartum period, ori-
ented mostly by phone, which was conducted in a less
favorable socioeconomic context [38].
The DPP and the DPS [2, 3], focused their dietary inter-
ventions on a decrease in calories and fats, especially satu-
rated fats, and the DPS also on an increase in fiber.
However, it is also important to consider new knowledge
that has developed since the publication of these studies.
An intervention based on a Mediterranean diet, supple-
mented with either olive oil or nuts, was more effective than
a low-fat diet in the prevention of diabetes [39]. Systematic
reviews of observational studies suggest that increased con-
sumption of red meat and especially processed meat are re-
lated to a higher incidence of diabetes [40], and that
increased consumption of dairy products is related to a
lower incidence [41, 42]. Additionally, a systematic review
of observational studies has strengthened the evidence that
increased consumption of food rich in fiber is associated to
a lower incidence of diabetes [43]. Consumption of ultra-
processed foods, likely to play an important role in the
current obesity epidemic, may also be related to the inci-
dence of diabetes. In Brazil, sugars, margarine, salt and pasta
already seasoned for preparation, as well as ultra-processed
foods (fast foods and convenience foods such as snacks and
desserts which are pre-prepared and ready-to-eat) are in-
creasingly being consumed [44], and ultra-processed foods
have been found to be associated with obesity [44, 45].
Artificial sweeteners, frequently used in Brazil to
sweeten coffee and tea, have been recently shown to
drive the development of glucose intolerance in rodents
through direct compositional and functional alterations
in the intestinal microbiota [46]. In humans the associ-
ation between artificially sweetened beverage intake and
glycemic level is inconsistent, and positive associations
have been suggested to be due to reverse causality [47].
Coffee (independent of being decaffeinated or not) as
well as tea consumption have been related to lower risk
for diabetes in meta-analyses of observational studies
[48]. Although both are a major source of anti-oxidants
and coffee has anti-inflammatory effects, the physiologic
basis for a purported effect is still unknown [49]. Small,
short term (weeks) clinical trials have shown mainly
negative results. The longest (16 weeks) trial, however,
showed a slight, though questionable, benefit [50–53].
Moderate maternal consumption of caffeine during lac-
tation does not appear to adversely affect the newborn,
although more studies are needed [54].
Finally, advances in the use of internet and telephone-
based interactions can facilitate interventions in the
postpartum period, as they permit a more home-based
approach. In at least one study these strategies have
been found to be as effective as face-to-face coaching in
achieving weight loss [55]. Additionally, barriers to suc-
cessfully treatment of obesity in low resource settings
may be overcome by the use of technology-assisted
weight loss interventions. A recent systematic review has
shown that compared to usual care, technology-assisted
interventions in the primary care setting help patients
achieve weight loss [56].
Objectives
The aim of this study is to investigate the effectiveness
of a lifestyle intervention program in delaying or pre-
venting type 2 diabetes when implemented after a preg-
nancy complicated by GDM in women identified as
being at higher risk.
Additionally, we aim to investigate factors related to
success or failure in diabetes prevention, to develop ma-
terials and expertise to assist in the development of dia-
betes prevention programs, and to contribute to public
policies for diabetes prevention in primary health care.
Methods
Design
LINDA-Brasil is a multicenter randomized clinical trial to
test the effectiveness of a lifestyle intervention program (of
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18 to 60 months) in delaying or preventing type 2 diabetes
when implemented shortly (10 weeks to 2 years) after a
pregnancy complicated by GDM in women identified as be-
ing at higher risk (use of insulin during pregnancy and or
post-partum lesser-than-diabetes hyperglycemia). Figure 1
illustrates the flow of participants through the trial, from re-
cruitment to completion of the study.
Recruitment and eligibility
All women aged 18 or older identified as having GDM
at pre-natal clinics in selected Brazilian cities, regardless
of the diagnostic criteria, and living within distance per-
mitting an easy access to the trial sites, are invited to
participate.
At first contact, the study protocol is explained and an
initial signed consent is obtained. Information regarding
socio-demographics, reproductive history, pre- and early
gestational weight, gestational age, GDM diagnosis and
treatment as well as dietary, physical activity and smok-
ing habits is obtained through interviews and chart re-
view. Folders regarding the importance of preventing
diabetes and of breastfeeding are distributed. If recruited
during pregnancy and the immediate postpartum period,
women are monitored monthly by telephone until eligible
to begin the trial. Date and place of birth are obtained and
intention to breastfeed evaluated. Additionally, we inquire
about the use of insulin and or oral antidiabetic medica-
tion during later pregnancy and obtain the last measured
pregnancy and postpartum weights.
Although entrance is permitted up to 2 years postpar-
tum, eligible women are encouraged to enter the trial as
early as 10 weeks after pregnancy. Those who used insu-
lin during pregnancy are automatically eligible. Eligibility
for remaining women is assessed by a 2 h 75 g oral glu-
cose tolerance test (OGTT) performed after the sixth
postpartum week. Women presenting impaired fasting
glucose (fasting plasma glucose ≥ 100 mg/dl; 5.6 mmol/
L) or impaired glucose tolerance (2 h plasma glucose ≥
140 mg/dl;7.8 mmol/L) [57] on this testing are eligible.
The following exclusion criteria apply:
 confirmed diabetes (two abnormal OGTTs), [57] or
one OGTT with unequivocal values [abnormal
fasting and 2 h plasma glucose values; fasting
plasma glucose ≥140 mg/dl (7.8 mmol/L) or 2 h
glucose ≥270 mg/dl (15 mol/L)];
 current use of antidiabetic medication;
 normal glucose tolerance (if not using insulin during
pregnancy);
 an indication that the trial interventions are not
feasible, for example, due to relocation to a place
distant from the trial site or a poor response in
previous contacts (e.g., lack of interest in phone
interviews);
 a body mass index ≥ 40 kg/m2; and
 health limitations or treatments (assessed by
questionnaire) which would restrict the nutritional
intervention or the ability to practice physical
activity, affect glucose tolerance or limit
participation or survival.
With respect to this last criterion, the presence of the fol-
lowing chronic conditions indicate exclusion: cancer requir-
ing treatment in the past 5 years (except those which have
been cured or carry an excellent prognosis); certain infec-
tious diseases (HIV positivity or active tuberculosis); clinic-
ally important cardiovascular disease (recent hospitalization
or congestive heart failure requiring use of a diuretic or
digitalis preparation); uncontrolled hypertension (systolic
blood pressure ≥180 mmHg or diastolic blood pressure
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current or
recent
GDM 
Phone 
follow-up 
and glucose 
testing
Random
allocation
Recruitment and
assessment of eligibility
Clinical trial
Randomization, intervention
and outcome as certainment
(18 months - 5-years)
Baseline exams
and trial
enrollment
Intervention
Control
Clinic visits
Outcomes
Outcomes
Initial
written
consent
Written
consent for 
trial
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Fig. 1 Description of the study protocol, including major actions taken during each of its phases
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≥105 mmHg on treatment); certain gastrointestinal diseases
(chronic hepatitis or cirrhosis, alcoholic hepatitis or alco-
holic pancreatitis; inflammatory bowel disease requiring
treatment in the past year; recent or significant abdominal
surgery (e.g. bariatric surgery); chronic renal failure; certain
lung diseases (chronic obstructive pulmonary disease or
asthma requiring daily therapy); a major psychiatric dis-
order (e.g. severe depression); and anemia not caused by
iron deficiency.
Women not entering the trial are followed with yearly
assessment of hyperglycemia until trial completion in
order to derive external control estimates for the princi-
pal trial outcomes.
Baseline measurements and trial enrollment
At baseline, women respond to a standardized questionnaire
and undergo physical measurements. Data on prenatal care
and delivery are extracted from the health care record car-
ried by the participant. Questionnaires address risk factors
for type 2 diabetes, including eating and drinking behaviors,
physical activity [58], sedentary habits [59–61] as well as is-
sues such as quality of life [62], depressive symptoms [63],
perceived body image trajectories [64], quality and duration
of sleep [65], medication use, and perceived risk of diabetes
[66]. A physical examination includes blood pressure, waist
and hip circumferences, weight, height, body composition,
fitness assessment [67] and abdominal height [68]. Addition-
ally, physical activity is assessed using accelerometers (Acti-
Graph GT3X) worn on the waist for seven days.
A standardized 75 g OGTT [57] is done with samples
taken at fasting and 30, 60, 90 and 120 min [69]. A urine
sample is collected upon arrival. Aliquots of serum,
plasma, urine and DNA are stored for future measure-
ments. To assure that women who used insulin during
pregnancy and had not undergone a postpartum OGTT
have not developed diabetes, their fasting and 2 h glu-
cose values are determined prior to randomization. After
key aspects of the clinical trial protocol are reviewed and
remaining questions are clarified, an additional written
informed consent is obtained and a further visit to the
clinic is scheduled.
At this second baseline visit, women complete exams, in-
cluding a six minute walking test. After eligibility has been
once more confirmed (including the absence of diabetes),
and key aspects of the protocol, including randomization,
have been reviewed, women are enrolled into the trial.
Participants missing the scheduled visits are rescheduled
when justified. Missing three appointments is a criterion
for exclusion from the clinical trial. In this sense, these
preparatory visits also serve as a run-in period for the trial.
Randomization
Women are allocated to one of the two comparison
groups. The computer generated randomization scheme
is 1:1 by trial arm, stratified by center and performed in
random blocks of sizes 4 and 6 participants. Treatment
is allocated automatically, with clinical staff soliciting
and then receiving the treatment allocation through the
secure, password protected data entry system to guaran-
tee adequate concealment of allocation.
Intervention groups
✓ Control Group: Less intensive conventional care for
women with prior GDM. This group receives a booklet
containing instructions about diabetes prevention and
materials based on current guidelines with
recommendations for breastfeeding, physical activity and
healthy eating. They are informed about the benefits of
periodically checking their diabetes status and that such
an assessment will be provided annually during the trial.
✓ Intervention Group: A more intensive program
designed to promote and support healthy behaviors
likely to prevent diabetes. In addition to receiving the
above materials, women in this group receive
participant-centered coaching focused on prolonging
breastfeeding, weight control and a healthy life style
with emphasis on the quality of their diet and physical
activity. Coaching is primarily done by phone, and
registration of weight and steps taken is encouraged.
Key aspects of the intervention
Intervention is tailored so as to meet the particular needs
of women with previous GDM during their postpartum.
Building from social cognitive theory [70], interventions
are participant-centered [71–73], allowing adaptation to
each women’s setting, within the limits of a standardized
prevention program with defined goals and structure.
Communication strategies are based on motivational inter-
viewing [14] and health coaching approaches implemented
in the primary care setting [74].
The specific components of the intervention and cor-
responding goals are:
 Promotion and support for exclusive breastfeeding
for up to six months of life and partial breastfeeding
thereafter for at least three additional months.
 Stimulation and support for personally-monitored
weight loss and maintenance with the goal of returning
to pre-pregnancy weight and, for those overweight or
obese pre-pregnancy, losing at least an additional 5 %
of body weight. If this goal has already been achieved
at randomization, the treatment goal will be a loss of
5 % of current body weight or that needed to achieve a
BMI of 22.5 kg/m2.
 Promotion of healthy eating, emphasizing avoidance
of ultra-processed foods, limited intake of oils,
sugars and processed meats, increased intake of
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foodstuffs in their natural state, regular intake of
water and dairy products, and intake of coffee and
tea without sugar or sweeteners.
 Encouragement and support for a personally-
monitored progressive increase in physical activity
with an initial goal of breaking up extended bouts of
sitting with ambulatory activity, reduction of seden-
tary behavior (defined as <5000 steps/day); and later
striving to perform at least 150 min of moderate or
vigorous physical activity/week (7500 steps/day with
at least 30 min. taken at a cadence of 100 steps/
min.) [75–77].
Table 1 summarizes the progressive nature of the life-
style interventions which takes into consideration the par-
ticularities of recent motherhood, the gradual changes
promoted, and the allowance of participant-centered ap-
proaches in the progression towards the final goals.
During the first stage, coaching is conducted primarily
to achieve gradual weight loss. Healthy eating and reduc-
tion of sedentary behavior are also emphasized and are
the main focus for those who do not need to lose weight.
Initial changes are promoted in accordance to participant
desires and needs, and take into consideration the fact
that most women will be breastfeeding (many exclusive
breastfeeding) and still adapting to recent motherhood.
During the second stage, which is likely to occur after
exclusive breastfeeding has terminated, while still aiming
to achieve/maintain weight loss, we place emphasis on
increasing physical activity. The third stage aims at
maintaining progress achieved by monitoring goals, de-
tecting relapses and preserving fidelity to the trial.
The main approaches used to deliver the intervention
are described in Table 2, the principal approach being
phone sessions, complemented by phone texting (SMS).
Phone sessions occur initially at a weekly interval (3 ses-
sions), then biweekly and, when weight goal is achieved,
monthly for about one year. After the first year the
frequency of phone sessions decreases and phone texting
becomes the principal way of communication. Group
sessions and social events are optional, to be used when
felt needed throughout the study.
Trial outcomes
Follow-up will continue until all women have completed
at least 18 months of participation and the average
length of follow up for the whole sample is at least three
years. Data and safety monitoring issues are addressed in
a specific section below. Strategies for maximizing ad-
herence to the Study have been developed. Outcomes
are assessed at baseline, then generally again at 6 months,
and then annually. (Table 3)
Primary Outcome: The primary outcome is incident
type 2 diabetes, which will be ascertained by OGTT and
HbA1C in both groups. At study close-out, all women
whose last ascertainment occurred more than 6 months
previously will be reassessed.
Secondary Outcomes:
1. Normalization of intermediate hyperglycemia
(fasting and 2 h blood samples, HbA1C) [57]
2. Metabolic syndrome (fasting blood samples,
questionnaires) [78]
3. Mean insulin resistance, beta cell function (OGTT) [69]
4. Mean weight loss and weight goal achievement
5. Physical fitness (6 min. test [67], handgrip; sit and
reach test)
6. Duration of breastfeeding and rate of exclusive
breastfeeding up to 6 months postpartum (phone
interviews between 6 months and 1 year
postpartum)
7. Quality of life [62]
8. Mean body fat/central fat (weight, % body fat, waist
circumference and abdominal height)
9. Sleep quality (Pittsburg questionnaire) [65]
10.Perceived body image (questionnaire) [64]
Table 1 Progressive nature of lifestyle interventions for weight control, healthy eating and an active lifestyle
Stage 1 Stage 2 Stage 3
8-12 weeks 8 a 26 weeks Up to close out
Weight control Initiating weight loss (up to 2 kg/month
while breastfeeding) when needed.
Achieving further weight
loss to goal when needed/
weight maintenance.
Maintaining weight
(additional weight loss
if needed).
Goal: return to pre-pregnancy weight and, for those
overweight or obese prior to pregnancy, loss of at least
an additional 5 % of body weight.
Healthy eating Developing healthy eating. Overcoming difficulties to
sustain healthy eating.
Maintaining healthy
eating.
Active life style Developing an active lifestyle. Developing an active lifestyle. Maintaining/enhancing
an active lifestyle.
Goal: breaking up extended bouts of sitting with ambulatory
activity; reducing sedentary behavior (defined as
<5000 steps/day).
Goal: increasing physical activity to
at least 150 min of moderate or
vigorous physical activity/week, or
7500 steps/day.
Schmidt et al. BMC Pregnancy and Childbirth  (2016) 16:68 Page 6 of 12
11.Depressive symptoms (Edinburgh questionnaire) [63]
12.Infant growth (reference curves)
13.Adverse events
Process outcomes:
1. Dietary quality (dietary recalls)
2. Intensity and duration of physical activity (Number
of minutes spent in moderate to vigorous intensity
activity and the number of minutes spent in
sedentary activity, estimated by accelerometer; and
percentage of women achieving the moderate or
vigorous physical activity goal of 150 min/week,
estimated by the leisure-time and transportation sec-
tions of the International Physical Activity Question-
naire - IPAQ, long version [58])
3. Percentage of women adhering to the protocol of
intervention (phone sessions and outcome monitoring)
Table 2 Approaches of the intervention
Approach Description
Motivational interviews An initial 30–40 min session informs baseline results; evaluates motivation and self-efficacy; and sets individual
goals to establish an initial action plan. Additional sessions occur during pre-defined clinic visits.
Phone sessions Phone sessions are the principal means of delivering the intervention. A minimal core curriculum will be covered,
but the sequence and frequency of the sessions will be tailored to each participant’s needs. During weight loss,
frequency may be weekly or bi-weekly, but in general, monthly sessions are planned for the first year.
SMS texting Texting is used for reminders of exams and monitoring of weight and steps. With the progression of the intervention,
when phone contacts are reduced in frequency, texting will be used to maintain motivation and adherence.
Group sessions (as needed) Specific topics are addressed, focusing on aspects which most benefit from group interaction. Participants are
invited to attend sessions as needed.
Social activities (optional) These optional activities include culinary workshops and group walks.
Table 3 Measurements used to determine trial outcomes
Measurements Times of measurement
during follow upa
Main outcomes
Exams
75 g oral glucose tolerance test 6 months, annual Diabetes/intermediate hyperglycemia
[57]; insulin resistance [69]
Glycated hemoglobin 6 months, annual Diabetes [57]
HDL-C, triglycerides 6 months, annual Metabolic syndrome [78]
Weight 6 months, annual Weight loss/maintenance
Height
Blood pressure, heart rate (Omron 765CP, Omron, Kyoto, Japan) 6 months, annual Metabolic syndrome [78]
Waist and hip circumferences 6 months, annual Metabolic syndrome [78]
Abdominal height (Holtain-Kahn caliper, Seritex, Tinton Falls, NJ, United States) 6 months, annual
Percent body fat (InnerScan BC-1500,Tanita) 6 months, annual
Handgrip strength (Jamar hydraulic hand dynamometer); 6 min walking test; sit and
reach test (Wells bench, Wood-WCS)
6 months, annual
Accelerometry (ActiGraph WGT3X) 6 months, annual Reaching 7500 steps/day [75]
Questionnaires
Quality of life [62] Annual
Depressive symptoms (Edinburgh questionnaire) [79] 6 months, annual
Perceived body image [64] and diabetes risk [66] Annual
Sleep quality (Pittsburg questionnaire) [80] Annual
Breastfeeding status 6 months, 1 year Duration of exclusive and
overall breastfeeeding
Dietary recall/registry 6 months, annual
Physical activity and sedentary behavior (IPAQ long version, leisure-time
and transportation sections [58]; sedentary behaviors questionnaire) [59–61].
6 months, annual
aAll taken at baseline
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Table 4 Timeline of main activities from recruitment to the end of the clinical trial
Activity Recruitment for the trial and follow-up of those not entering the trial Clinical trial
Pregnancy Perinatal period Post-pregnancy period (weeks)
Recruitment Telephone contact Trial
preparation
Baseline
measures
Follow-
upa
All women entering the trial
Post-randomization follow-up (months)
Gestational weeks 20–40 Pregnancy to
30 days postpartum
4–104 8–104 Up to 260 0 0–6 6–12 12–24 24–36 36–48 48–60
Consents x x
Entry x x x Trial randomization
Interviews/exams/
chart reviews
x x x x x x x x
Phone contacts x x x
Baseline and follow-
up measurements
x x x x x x
Material
distributions
Breastfeeding folder 1; Pregnancy
to postpartum booklet
Mail at birth:
Breastfeeding
folder 2
Project folder Preventing diabetes booklet
Intervention group
Motivational
interviews
x x x x
Phone sessions x x x x x x
SMS texting x x x x x x
Group sessions As needed
Social events As needed
Mailings As needed
aFollow-up of those not entering the trial
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4. Participation in optional activities: group sessions
and social events.
Follow-up
The timeline of study activities during recruitment and
the clinical trial is shown in Table 4. Follow-up of those
not entering the trial is also included in the table.
At trial follow-up visits, glucose determinations are
performed by staff blinded to patient allocation. Princi-
pal investigators, clinical staff, outcome assessors and
participants are blinded with respect to glucose results
for the duration of the trial. Women who reach diabetes
glucose levels are notified. Given that follow up the par-
ticipants occurs at yearly intervals, we do not require
confirmation of the diabetes status on another day to as-
certain incident diabetes in order to avoid an excessive
length of time prior to the initiation of medical care for
diabetes.
Sample size
We estimated that the control group will have a cumula-
tive 3-year diabetes incidence rate of 25 %. This estimate
lies between a lower rate (19 %) found in a trial involv-
ing women considerably leaner [9] and higher rates
found in two trials: a trial of a very high risk postpartum
group (36 %) [8] and another trial involving older
women, enrolled a decade after their first pregnancy
with GDM (38 %) [4]. We also assume that the interven-
tion will produce a reduction of 40 % in diabetes inci-
dence over three years. This estimated effect is lower
than the incidence reduction observed in the DPP sub-
group analysis (53 %), consistent with our anticipated in-
tervention’s effect, and clinically meaningful for the
prevention of diabetes in Brazil. The number needed to
treat to prevent one case of diabetes is 10 (1/(.25-.15).
Under an exponential model, the relative risk of 0.60
comparing intervention to control corresponds to a haz-
ard ratio of 0.565.
We based our sample size calculation on a Cox pro-
portional hazards model test of a one-sided primary hy-
pothesis (no difference between treatments in incidence
of type 2 diabetes) at the 0.025 level, with 90 % power,
using the package RCTdesign in the software R, version
2.14. Utilizing a group sequential design, we plan for
four analyses, three interim and one final with symmet-
ric O’Brien-Fleming boundaries for efficacy and futility
to be spaced evenly in information time. This analysis
shows that 135 observed events in both arms are needed
at the time of final analysis to have 90 % power to detect
a true hazard ratio of 0.565. Assuming an annual drop-
out rate of 5 %, an average monthly recruitment of 18
participants, and requiring an average follow-up time of
three years if the study continues to the final analysis,
we calculated a total sample size of 740 for the trial.
To enroll this number of women, we estimate that up
to 7400 women will have to be initially screened. If we
are unable to maintain our monthly recruitment goals
with the strategy outlined above, we will consider other
means of recruitment.
Ethical issues
The trial protocol was approved by the ethics committee
of the Hospital de Clínicas de Porto Alegre (Project
120097, May 4, 2012). Written consent is obtained at
initial recruitment and then again, before enrollment to
the trial. At randomization we explain to the participants
that they will have equal chances of being entered into
one or the other group. We also explain that it is not
known whether applying a more intense intervention
relatively soon after postpartum is more beneficial than
the conventional approach. However, if the Study finds
that it is indeed more beneficial, then at study close-out
those who did not receive the more intense approach
will be informed about how to undertake the activities
found to be successful. While we emphasize the import-
ance of maintaining participation throughout the study
so as to minimize bias in the trial results, women are in-
formed that they may request to terminate participation if
they so decide. Those who drop out of the study will
nevertheless have their available follow-up time in-
cluded in analysis of treatment effects. Women found
to have developed diabetes will be notified and ori-
ented to seek medical attention to confirm diagnosis
and initiate treatment.
A data and safety monitoring board (DSMB) will
monitor efficacy (or futility) and adverse effects. Based
on these considerations, the DSMB may recommend
that the protocol be modified or that the LINDA trial be
terminated. The DSMB will consist of experts in relevant
biomedical fields, biostatistics and medical ethics.
Final considerations
After testing instruments and piloting strategies and
procedures, we initiated trial recruitment and
randomization in January, 2015.
Discussion
To our knowledge, this is one of the few randomized tri-
als designed to prevent diabetes by intervening shortly
after delivery of women with GDM. As such, the experi-
ence gained with respect to the specific issues related to
intervention during this special phase of women’s lives
should add important knowledge to the field of diabetes
prevention worldwide.
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